PAC-1 Enters New Human Trials for Brain Cancer

Nov 27, 2017 / In the News

EurekAlert (Nov. 27) – A drug that spurs cancer cells to self-destruct has been cleared for use in a clinical trial of patients with anaplastic astrocytoma, a rare malignant brain tumor, and glioblastoma multiforme, an aggressive late-stage cancer of the brain. This phase Ib trial will determine if the experimental drug PAC-1 can be used safely in combination with a standard brain-cancer chemotherapy drug, temozolomide.

Also in:

* News-Gazette (Nov. 28)

* European Pharmaceutical Review (Nov. 29)